Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .It’s time to talk about my single-biggest investment, LandBridge Company LLC ( LB ) , which isn’t just important because of its 20% weighting in my portfolio, but also because it perfectly captures a wide range of my bullish theses, including these major themes:Leo Nelissen is a ...

Group 1 - The article emphasizes the importance of in-depth research on various income alternatives including REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs [1] - The author has achieved a personal record in the time taken to write the article, indicating a commitment to thorough analysis [1] Group 2 - Leo Nelissen is identified as an analyst focusing on significant economic developments related to supply chains, infrastructure, and commodities, contributing to actionable investment ideas [2] - The analysis provided by Leo aims to highlight dividend growth opportunities, which are crucial for investors seeking income [2]

Core Insights - The article discusses the importance of understanding long-term purchasing power and its implications for investment strategies [1]. Group 1: Analyst Background - Leo Nelissen is an analyst focused on major economic developments related to supply chains, infrastructure, and commodities [1]. - He is a contributing author for iREIT®+HOYA Capital, aiming to provide insightful analysis and actionable investment ideas, particularly in dividend growth opportunities [1]. Group 2: Investment Opportunities - The article emphasizes the significance of dividend growth opportunities as a key area for potential investment [1].

Global Trade & Economy - Global trade is becoming increasingly complex due to strategic decoupling, nearshoring, and tariffs [1] - Supply chains are under pressure, leading to rising inflation [1] - Market fragmentation is occurring [1] - The question of whether the world is truly deglobalizing is being raised [1] Bloomberg New Economy Forum - The Bloomberg New Economy Forum will be held live in Singapore from November 19-21 [1] - The forum will cover the aforementioned topics related to the global economy [1]

US-China Trade Relations & Rare Earths - The US is trying to reduce its dependence on China for rare earths, while China is trying to jumpstart its economy [1] - The US exports rare earths to China, highlighting that the problem is refining, not reserves [3] - A short-term deal between the US and China could involve delaying Chinese controls on rare earth products and resuming US soybean exports to China, but this requires the US to concede something [7] - China may delay implementation of controls on rare earth products but will continue building up that mechanism and could expand to other supply chains like fine chemicals used in drugs [8] Supply Chain Vulnerabilities & Strategies - The US faces a serious long-term challenge across a broad range of supply chains [8] - Working with allies is crucial for the US to counter supply chain vulnerabilities quickly [9] - Australia can help the US on rare earths, and Japan has technology and experience dealing with Chinese embargoes [10] - The US long-term policy should focus on supply chains rather than trade balances and tariffs [11] China's Long-Term Strategy - China has a long-term strategy to build up its production capacity, especially in advanced technology, to exert coercive pressure on other countries [15][16] - China's goal is to become more important globally, allowing it to exert more pressure on the US and other countries [16]

China imposed sanctions on five of a South Korean shipping company's US subsidiaries effective immediately. This comes as the US also begins collecting steep fees from Chinese ships coming to the US imposed under section 301. All of this the latest moves in the tip fortat trade war that sent stocks tumbling Friday and again today.I'm joined by Terry Haynes, Pangia policy founder and the Zach Necktar Wy Rain LLP chair who served from 2018 to 2021 in the Department of Commerce as assistant secretary and under ...

There are tremendous opportunities for Canada. And I would say to Southeast Asia, and you heard me say this before, come to Canada. I mean, you know, we're here at the Milken Institute.We're talking about capital. So much of the capital today is talking about where is it that they can actually find places for global diversification. I would say Canada is a great place because the other thing we hear from so many of the capital investors here is they're looking for predictability.They're looking for countrie ...

Sticking with that trade front, President Trump says he's spoken to Indian Prime Minister Narendra Modi, in a move that could ease tensions between the two major economies. The call came after the two nations resumed trade negotiations. Let's get more with our senior editor, Derek Wallbank, joining us for more.I mean, Derek, I found it so interesting. You can see in that social media post that he said he had a wonderful call with India's Narendra Modi. But how did that become a wonderful call.When you look ...

Production & Trade - A significant portion of the company's product manufacturing is currently located in Mexico, benefiting from trade agreement exemptions [1] - The company is cautious and does not take current trade advantages for granted [1] - Shifting a substantial amount of production to America presents challenges, including costs, labor acquisition, and training, requiring a considerable timeframe exceeding one to two years [2] Pricing & Value Proposition - The company believes it currently possesses pricing power [1] - The company aims to maintain a strong value proposition for consumers [2] Brand & Identity - The company intends to stay true to its core identity, focusing on delivering high-quality products [3]

Core Insights - The pharmaceutical industry has historically been protected from tariffs due to long-standing trade agreements, but the current administration's focus on bringing manufacturing back to the U.S. poses new challenges [1][2] - President Trump has proposed tariffs of up to 25% on imported pharmaceuticals, with potential updates expected in early April [2] - The imposition of tariffs would represent a significant shift for the industry, reversing the effects of a 1994 World Trade Organization agreement that eliminated levies on many pharmaceutical products [3] Industry Impact - Analysts indicate that the pharmaceutical companies have benefited from low tax rates in countries like Ireland, which has attracted U.S. pharmaceutical firms [4] - The complexities of global tax strategies and supply chains may delay companies' ability to adjust to new tariffs, leading to potential negative impacts [5] - Companies such as Merck, AbbVie, Amgen, and Pfizer are identified as facing the highest risks from potential tariffs, while others like Eli Lilly and Gilead have more moderate risks [6]